newsfilter
← Latest News
Business Wire·

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

– Key Data Readouts from Sentinel Participant Expected in 2Q 2025 and 3Q 2025 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies